First dose of Pfizer, AstraZeneca shots cut transmissions, hospital risk, say UK studies

The first country to start major vaccines in December, more than 17 million UK residents have received at least the first dose so far.

Representative image of COVID-19 vaccine candidate. Image: Imperial College London via AP

Data from two different studies published in the UK on Monday, one in England and another in Scotland, have revealed vaccines. COVID-19 effective in cutting the transmission of diseases and hospitals from the first dose. A study from Public Health England has shown that the vaccine made by Pfizer-BioNTech reduces the risk of infection by more than 70 per cent after the first dose. That risk is reduced by 85 percent after a second dose. The public health body’s study of worldwide data also showed that vaccinated people who go on to become infected are far more likely to die or go into hospital.

Hospitalization and death from COVID-19 reduced by more than 75 percent in those who received a dose of the Pfizer-BioNTech vaccine, according to the analysis.

“This important report shows that vaccines work – it is very encouraging to see evidence that the Pfizer vaccine offers a high level of protection against corona-virus , “Health Secretary Matt Hancock said.

Britain is one of the hardest hit countries COVID-19 pandemic, with 1,20,757 deaths.

It was the first country to start major vaccines in December and more than 17 million people have now received at least the first dose of vaccine – a third of the UK adult population.

“We will see a lot more data over the coming weeks and months but we should be very encouraged by the first results,” said Dr Mary Ramsay, Head of Vaccination at Public Health England.

First dose of Pfizer shots AstraZeneca cuts hospital discharge risk says UK studies

Production image. Credit: US Navy / Chief Personal Officer Anthony Sisti

Evidence from nationwide studies

Meanwhile a study in Scotland has shown that the Pfizer-BioNTech and Oxford-AstraZeneca vaccines have led to a reduction in COVID-19 admission to hospitals after the first dose.

The study, led by the University of Edinburgh, found that the fourth week after receiving the first dose of the Pfizer vaccine reduced hospital risk from COVID by up to 85 percent.

The Oxford-AstraZeneca vaccine reduced the risk by 94 per cent.

“These results are very encouraging and have given us great reasons to be optimistic about the future,” Dr Aziz Sheikh, who is leading the research, said in a statement. we now have – across the whole country – that a vaccine protects against it COVID-19 ospadalan.

“The first worldwide dose of vaccines needs to be accelerated to help overcome this terrible disease,” he said.

The research compared the results of those who had their first injection with those who did not.

It found that vaccination was associated with an 81 percent reduction in hospital risk in the fourth week among those aged 80 years or older, when the results for the two vaccines were combined.

‘Extremely promising’

The project, which used patient data to monitor pandemic and real-time transmission of the vaccine, analyzed a dataset covering Scotland’s total population of 5.4 million between 8 December. and 15 February.

Around 1.14 million vaccines were given to 21 per cent of the Scottish population during that period.

The Pfizer vaccine was administered to 6.50,000 people in Scotland, and 490,000 received the Oxford-AstraZeneca vaccine.

This is the first study to describe the impact of vaccines on the prevention of serious hospital-acquired illnesses across the country.

Previous results on vaccine efficacy have come from clinical trials.

The study team said the findings were relevant to other countries using the Pfizer and Oxford-AstraZeneca vaccines.

The data reported are “very promising,” said Arne Akbar, president of the British Society of Immunology.

“While there appears to be some variation in efficacy levels measured across age groups, the decline in hospitals for older age groups is still very high,” he said.

“We now need to understand how long this protection lasts for one dose of the vaccine.”